Xenetic Biosciences Inc Revenue per Employee (XBIO), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Xenetic Biosciences Inc   (NASDAQ: XBIO)
 

Xenetic Biosciences Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Xenetic Biosciences Inc 's Revenue per employee fell on a trailing twelve month basis to $ 1,479,539, but the productivity of Xenetic Biosciences Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 45 other companies have achieved higher revenue per employee. While Xenetic Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 485 to 541. Xenetic Biosciences Inc has 2 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XBIO Revenue per Employee (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Revenue Change -29.38 % 11.99 % 36.01 % 18.11 % 67.19 %
Sales per Employee (TTM) $ 1,479,539 1,630,389 1,595,037 1,488,206 1,429,468
XBIO's Total Ranking # 541 # 485 # 2275 # 2482 #
Seq. Revenue Change 9.79 % -18.13 % 5.3 % -25.38 % 74.09 %

XBIO Company Profile >> Back to XBIO Efficiency Comparisons >> Compare XBIO Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 46
Overall Market # 541

Revenue per Employee Statistics
High Average Low
$ 2,573,294 $ 1,034,610 $ 151,338
(Dec 31 2016)   (Sep 30 2020)



Financial Statements
Xenetic Biosciences Inc 's Revenue MRQ $ 1 Millions Visit XBIO's Income Statement
Xenetic Biosciences Inc 's Revenues TTM $ 3 Millions Visit XBIO's aggregate revenue growth
What are XBIO's Sales? Visit XBIO's Sales by Segment




Other Ratios
Xenetic Biosciences Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
XBIO's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for XBIO's Competitors
Revenue per Employee for XBIO's Suppliers
Revenue per Employee for XBIO's Customers

You may also want to know
XBIO's Sales Growth Rates XBIO's Pe Price to earnings ratio XBIO's Receivables Turnover Ratio XBIO's Stock Quote
XBIO's Net Income Growth Rates XBIO's Ps Price to Sales ratio XBIO's Sales per Employee XBIO's Asset Turnover Ratio
XBIO's Net Margin XBIO's Pb Price to Book ratio XBIO's Financial Strength Ratios XBIO's Dividend Payout Ratio
Date modified: 2026-11-13T05:09:59+00:00




Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Sep 30 2026Number of Employees Sep 30 2026
Kiniksa Pharmaceuticals International Plc  2,584,598.36 $ 945.963  Million 366 
Aurinia Pharmaceuticals Inc   2,513,578.12 $ 321.738  Million 128 
Sarepta Therapeutics Inc   2,342,920.96 $ 1,956.339  Million 835 
Zevra Therapeutics Inc   2,304,065.57 $ 140.548  Million 61 
Nurix Therapeutics Inc   2,214,309.15 $ 701.936  Million 317 
Exelixis Inc   2,176,862.25 $ 2,496.861  Million 1,147 
Incyte Corporation  2,113,485.94 $ 6,010.754  Million 2,844 
Alnylam Pharmaceuticals Inc   2,005,296.80 $ 5,013.242  Million 2,500 
Neurocrine Biosciences Inc   1,850,850.00 $ 3,701.700  Million 2,000 
Tarsus Pharmaceuticals Inc   1,843,791.89 $ 682.203  Million 370 
Gilead Sciences Inc   1,822,823.53 $ 30,988.000  Million 17,000 
Mirum Pharmaceuticals Inc   1,803,166.67 $ 670.778  Million 372 
Eli Lilly And Company  1,729,240.00 $ 86,462.000  Million 50,000 
Alector Inc   1,684,165.05 $ 173.469  Million 103 
Rigel Pharmaceuticals Inc  1,656,396.55 $ 288.213  Million 174 
Jazz Pharmaceuticals Plc  1,632,569.55 $ 4,718.126  Million 2,890 
Krystal Biotech Inc   1,593,305.08 $ 470.025  Million 295 
Madrigal Pharmaceuticals Inc   1,560,590.16 $ 1,427.940  Million 915 
Bristol myers Squibb Company  1,539,476.92 $ 50,033.000  Million 32,500 
Acadia Pharmaceuticals Inc   1,506,642.86 $ 1,202.301  Million 798 
Indivior Pharmaceuticals Inc   1,376,000.00 $ 1,376.000  Million 1,000 
Biogen Inc   1,372,973.33 $ 10,297.300  Million 7,500 
Supernus Pharmaceuticals inc   1,326,849.69 $ 865.106  Million 652 
Corcept Therapeutics Inc  1,320,064.38 $ 963.647  Million 730 
Travere Therapeutics Inc   1,309,927.57 $ 651.034  Million 497 
Lantheus Holdings Inc   1,309,212.07 $ 1,561.890  Million 1,193 
Heron Therapeutics Inc   1,167,640.63 $ 149.458  Million 128 
Ptc Therapeutics inc   1,166,048.44 $ 1,155.554  Million 991 
Abbvie Inc   1,158,140.35 $ 66,014.000  Million 57,000 
Biomarin Pharmaceutical Inc  1,134,780.19 $ 3,655.127  Million 3,221 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.